In the process of researching and writing my book, I’ve had conversations with interesting people who have unique, first hand perspectives on AI. I’ll be sharing some of these interviews here because I think some of you will enjoy reading them, and it’ll give you a taste of what’s to come in the book.

Follow updates on it here, including the presale that will be coming up!

The first interview I’ll be publishing is with IMVARIA. IMVARIA brings artificial intelligence to imaging and lab data, with non-invasive biomarkers that can completely revolutionize clinical assessments in serious diseases. Their first product is in market: FIBRESOLVE, the first FDA-authorized AI diagnostic tool for ILD (interstitial lung disease) and IPF (idiopathic pulmonary fibrosis).

(Full Disclosure: Creative Ventures is an investor in the company)

The founders, Dr. Joshua Reicher and Dr. Michael Muelly, are also both medical doctors and faculty at Stanford Health Care in Radiology. They also both worked at Google on AI and have numerous publications on it in prominent machine learning and AI journals. They have a rare perspective, sitting on "both sides of the table" between medicine and technology.

You can read the transcript below (edited for clarity) or listen to our conversation above.

Topics Discussed

* How did you become interested in AI and Medicine?

* What is the biggest impact AI could have in medicine in terms of clinical care for patients?

* What has changed in AI to make these things now possible?

* What are AI’s greatest weaknesses in medicine right now?

* What is your response to “deep learning is a black box”?

* Should humans be in the loop when working with AI in medical applications?

* Thoughts about Strawberry o1 results (for medical diagnosis)

* What is IMVARIA?

* How would you talk to other clinicians about AI and medicine?

* Why do you think radiology in particular has been resistant to adopting AI?

* What does a radiologist actually do?

* What has been the problem with clinical decision tools in the past?

* Do you think EMR data could become a big deal within AI and healthcare?

* What should not be replaced in AI and medicine in the near term?

* Will OpenAI and other foundational model companies take over in medicine?

* Why won’t China be the leaders in AI and healthcare?

* Impact of simulated or synthetic data in healthcare

* Final thoughts

This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit weightythoughts.com

AI's Future in Lung Disease and Medicine

Weighty Thoughts Podcast